APP
ADMS

Avantax Planning Partners’s Adamas Pharmaceuticals ADMS Stock Holding History

Avantax Planning Partners’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-27
Closed -$1K – 1662
2018
Q1 		$1K Buy
+27
New +$851 ﹤0.01% 1790

Other funds holding ADMS

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Avantax Planning Partners's ADMS Position: Q2 2018 in Review

Avantax Planning Partners sold out of Adamas Pharmaceuticals (ADMS) in Q2 2018, closing a stake of 27 shares — an estimated $1K sold.

Avantax Planning Partners first reported a position in ADMS in Q1 2018 and held it in 1 quarter. The position peaked at $1K in Q1 2018. 126 funds tracked by Wall St. Rank hold ADMS as of Q2 2018.

  • Avantax Planning Partners reported no remaining Adamas Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Avantax Planning Partners sold 27 Adamas Pharmaceuticals shares in Q2 2018, an estimated $1K.
  • Avantax Planning Partners first reported a position in Adamas Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • Avantax Planning Partners's Adamas Pharmaceuticals position peaked at $1K in Q1 2018.
  • 126 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2018.

Based on Avantax Planning Partners's 13F filing for Q2 2018, filed 13 Aug 2018.